Snedecor Sonya J, Strutton David R, Ciuryla Vincent, Schwartz Elissa J, Botteman Marc F
Pharmerit North America, Bethesda, MD 20814, USA.
Vaccine. 2009 Jul 23;27(34):4694-703. doi: 10.1016/j.vaccine.2009.05.062. Epub 2009 Jun 9.
We developed an age-structured, transmission-dynamic, mathematical model to quantify the direct and indirect benefits of infant PCV7 vaccination. The model simulates the acquisition of asymptomatic carriage of Streptococcus pneumoniae and the development of fatal and non-fatal invasive pneumococcal disease (IPD) among vaccinated and unvaccinated individuals aged <2, 2-4, 5-17, 18-49, 50-64, and >or=65 years old. The model was parameterized using published US surveillance data, supplemented with data from published literature. The model predicts the observed incidence of IPD with good agreement and may be used to predict the impact of various vaccination strategies in the US or other populations yet to introduce PCV7.
我们建立了一个按年龄分层的、传播动力学数学模型,以量化婴幼儿接种7价肺炎球菌结合疫苗(PCV7)的直接和间接效益。该模型模拟了2岁以下、2 - 4岁、5 - 17岁、18 - 49岁、50 - 64岁以及65岁及以上接种疫苗和未接种疫苗个体中肺炎链球菌无症状携带的获得情况以及致命和非致命侵袭性肺炎球菌疾病(IPD)的发生情况。该模型采用已发表的美国监测数据进行参数设定,并补充了来自已发表文献的数据。该模型对观察到的IPD发病率预测吻合度良好,可用于预测美国或其他尚未引入PCV7的人群中各种疫苗接种策略的影响。